COVID-19 Business Intelligence and Analysis for Clinical Laboratories, Pathology Groups and Hospital Administration

COVID-19 Briefings

Reliable COVID-19 Business Intelligence and analysis for clinical laboratories, pathology groups and Laboratory Diagnostics.

In Bid to Increase Serial Testing Capabilities, FDA Significantly Expands Authorization for Over-the-Counter COVID-19 Tests

FDA maze of regulations
Share on facebook
Share on twitter
Share on linkedin
Share on pinterest
Share on whatsapp
Share on email
Share on facebook
Share on twitter
Share on linkedin
Share on google
Share on whatsapp
Share on email

Three new authorizations granted by the FDA for over-the-counter and point-of-care COVID-19 tests used for serial testing

The US Food and Drug Administration (FDA) announced three new COVID-19 test authorizations to promote the availability of serial testing. All three tests had previous emergency use authorizations (EUAs), but these EUAs did not allow the flexibility to provide serial testing capabilities.

The new authorization for these tests expands their use to allow point-of-care testing or at-home, over-the-counter testing that was not previously permitted.

“Screening testing, especially with the over-the-counter tests authorized today, is an important part of the country’s pandemic response—many schools, workplaces, communities, and other entities are setting up testing programs to quickly screen for COVID-19,” Jeffrey Shuren, MD, JD, Director of the FDA’s Center for Devices and Radiological Health, said in a recent statement.

“The FDA has taken many steps to support test development throughout the pandemic,” Shuren continued, “including authorizing tests quickly, offering many avenues for test developers to work with us to get their tests on the market, if shown to be accurate and reliable, and issuing enforcement policies for COVID-19 tests. As the pandemic has progressed, we have worked with test developers wishing to add screening claims.”

The test authorizations listed by the FDA’s recent announcement include:
1. Quidel QuickVue At-Home OTC COVID-19 test—authorized for OTC at-home serial screening
2. Abbott BinaxNOW (multiple configurations)
• Abbott BinaxNOW COVID-19 Antigen Self Test—authorized for OTC at-home serial screening
• Abbott BinaxNOW COVID-19 Ag Card 2 Home Test— authorized for OTC at-home serial screening with telehealth proctor
• Abbott BinaxNOW COVID-19 Ag 2 Card—authorized for POC serial screening without a prescription
3. BD Veritor System for Rapid Detection of SARS-CoV-2—authorized for POC serial screening with a prescription

Related Resource:

FDA: FDA Continues to Advance Over-the Counter and Other Screening Test Development


Helping Your Lab Stay Afloat During Challenging Times

Dear Colleague,

Robert L. MichelIn these challenging times for our colleagues in clinical laboratories, pathology practices and hospital administration, The Dark Intelligence Group (TDIG) — through generous grants from our partners — is bringing you the COVID-19 STAT Intelligence Briefings.

We’ve added analysts, writers and skilled editors to the COVID-19 STAT team to uncover, analyze, and immediately report to you what’s happening with the SARS-CoV-2 pandemic, packaged with the insights you need to deliver quality testing for patient care and keep your lab’s financial ship afloat. As part of our mission, we are also bringing you real-time data from our partners around testing that you will not find anywhere else.

Please let me know how we can better improve this service to fit your needs. If you would like to offer a grant to keep our mission going with this site, please contact me at


Robert L. Michel
President, Founder
The Dark Intelligence Group